assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 5 mg/mL, clear
storage temp.
room temp
InChI
1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11)
InChI key
MDOJTZQKHMAPBK-UHFFFAOYSA-N
General description
Iniparib is also called as BSI-201. It is an anticancer agent.
Biochem/physiol Actions
4-iodo-3-nitrobenzamide, the intracellular metabolite of iniparib has the capability to covalently prevent PARP1 (poly(ADP-Ribose) polymerase 1) under cell-free conditions. PARP inhibitor also plays a role in BRCA (breast cancer susceptibility protein) deficient tumors.
Iniparib (BSI-201) is an antineoplastic originally thought to be a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. Recent studies indicate Iniparib is not a PARP-1 inhibitor, and its mechanism of action is currently unknown.
Iniparib (BSI-201) is an antineoplastic.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Fogelman DR, et al.
Anticancer Research, 31(4), 1417-1420 (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
O'Shaughnessy J, et al.
The New England Journal of Medicine, 364(3), 205-214 (2011)
Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro.
Patel AG, et al.
Clinical Cancer Research, 18(6), 1655?1662-1655?1662 (2012)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML0623-10MG | 04061832925851 |
| SML0623-50MG | 04061832925868 |